Novo Nordisk A/S ADR | Balance Sheet

Fiscal year is January-December. All values DKK Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
15,990
15,935
20,769
21,228
21,156
15,638
Total Accounts Receivable
15,406
17,528
20,734
24,197
21,123
23,799
Inventories
9,552
11,357
12,758
14,341
15,373
16,336
Other Current Assets
1,110
1,473
879
-
2,428
3,294
Total Current Assets
42,058
46,293
55,140
59,766
60,080
59,067
Net Property, Plant & Equipment
21,882
23,136
25,545
30,179
35,247
41,891
Total Investments and Advances
175
366
1,548
1,508
1,195
1,773
Long-Term Note Receivable
376
490
602
689
567
-
Intangible Assets
1,615
1,378
2,158
2,714
3,325
5,145
Total Assets
70,337
77,062
91,799
97,539
102,355
110,769
ST Debt & Current Portion LT Debt
215
720
1,073
229
1,694
Accounts Payable
4,092
4,950
4,927
6,011
5,610
Income Tax Payable
2,983
3,515
3,777
3,976
4,242
Other Current Liabilities
16,935
24,504
31,096
37,220
35,510
Total Current Liabilities
24,225
33,689
40,873
47,436
47,056
Provision for Risks & Charges
2,871
3,072
3,951
4,821
4,638
Deferred Taxes
3,559
5,392
6,800
2,670
1,095
Total Liabilities
27,768
36,768
44,830
52,270
52,540
Common Equity (Total)
42,569
40,294
46,969
45,269
49,815
Total Shareholders' Equity
42,569
40,294
46,969
45,269
49,815
Total Equity
42,569
40,294
46,969
45,269
49,815
Liabilities & Shareholders' Equity
70,337
77,062
91,799
97,539
102,355

About Novo Nordisk A/S

View Profile
Address
Novo Allé
Bagsværd CR 2880
Denmark
Employees -
Website http://www.novonordisk.com
Updated 07/08/2019
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following business segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity.